Hutchmed (China) Limited (HCM) ORD USD0.10
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Hutchmed China to make several presentations at cancer research meeting
5 April 2024 11:54
(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer...
-
Hutchmed endometrial cancer treatment gets priority review in China
2 April 2024 12:11
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and...
-
Hutchmed cancer treatment indication accepted for review in China
28 March 2024 13:02
(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by...
-
Hutchmed partner Inmagene exercises options over two drug candidates
2 February 2024 09:42
(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.
-
Hutchmed's 'Elunate' approved under new Hong Kong rules
30 January 2024 10:32
(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with...
-
Hutchmed application for thrombocytopenia treatment accepted in China
11 January 2024 11:11
(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted...
-
Hutchmed completes trial enrolment, keeps drugs on China funding list
13 December 2023 12:20
(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.
-
Hutchmed completes trial enrolment, keeps drugs on China funding list
13 December 2023 12:20
(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.
-
Hutchmed confirms new drug application for fruquintinib in Japan
29 September 2023 10:57
(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in...
-
Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale
14 September 2023 13:09
(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.
-
Hutchmed reports progress on two oncology fronts
12 September 2023 11:26
(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the...
-
Hutchmed tumour therapy candidate gets breakthrough designation
29 August 2023 13:38
(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough...
Company announcements Announcements
-
Vesting of Awards Under the LTIP
22 April 2024 09:30
HUTCHMED (China) Limited
-
2023 Annual Report and Notice of AGM
8 April 2024 09:30
HUTCHMED (China) Limited
-
LTIP and Share Option Scheme
14 March 2024 09:00
HUTCHMED (China) Limited
-
Vesting of awards under the LTIP
5 March 2024 08:30
HUTCHMED (China) Limited
-
2023 Full Year Results and Business Updates
28 February 2024 11:30
HUTCHMED (China) Limited
-
HUTCHMED to Announce 2023 Final Results
1 February 2024 08:30
HUTCHMED (China) Limited
-
Blocklisting Six Monthly Return
29 December 2023 08:30
HUTCHMED (China) Limited
-
Total Voting Rights
29 December 2023 08:30
HUTCHMED (China) Limited
-
Overseas Regulatory Announcement
21 December 2023 10:00
HUTCHMED (China) Limited
-
Overseas Regulatory Announcement
7 December 2023 10:04
HUTCHMED (China) Limited
-
Total Voting Rights
30 November 2023 08:30
HUTCHMED (China) Limited
-
U.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib)
9 November 2023 07:00
HUTCHMED (China) Limited
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.